Abstract 553P
Background
Next generation sequencing (NGS) has revolutionised the diagnosis of non-small cell lung cancer (NSCLC) yet it is resource-intensive. Exclusionary testing followed by NGS has been advocated as a cost-effective approach in Asians where EGFR mutations are prevalent. Herein we investigated the approach of plasma EGFR (pEGFR) followed by tissue NGS and compared it to upfront tissue NGS in terms of mutation detection and clinical outcome in a real world setting in Hong Kong.
Methods
We retrospectively reviewed 222 patients diagnosed with advanced NSCLC from October 2021 to April 2023, including 145 cases that performed upfront tissue NGS without prior pEGFR (group 1) and 77 cases that underwent pEGFR (Cobas v2) first. Among the latter group, 48 with positive pEGFR (group 2a) started target therapy while 29 with negative pEGFR (group 2b) proceeded further tissue NGS (Oncomine precision assay). Genomic alterations and clinical data were compared among these approaches.
Results
The median age was 70, 72 and 76 years old for group 1, 2a and 2b respectively. Extrathoracic disease was found in 54%, 90% and 41% of patients in each group. Regarding genomic alterations detected by tissue NGS, sensitising EGFR mutations were found in 39% of cases in group 1, compared to only 7% in group 2b (OR 0.11, p=0.001). Additional driver mutations (EGFR exon 20 insertion, T790M, ALK, BRAF, MET exon 14 skipping, ERBB2 exon 20 insertion and KRAS) were found in 27% of group 1 cases, but up to 52% in group 2b (OR 2.92, p=0.008). For patients with EGFR mutations detected by tissue NGS, 41% had concurrent TP53 or PIK3CA mutation, which are predictive markers. The median time from radiological diagnosis to treatment initiation was 18 days for patients with positive pEGFR compared with 41 days for the counterparts underwent tissue NGS.
Conclusions
The pathway of pEGFR preceding tissue NGS allows early detection of druggable EGFR mutations and initiation of target therapy for patients with extrathoracic NSCLC but lacks simultaneous detection of predictive markers. The liquid-first approach enhances the yield of rare mutations by tissue NGS which is resource-dependent. It benefits regions where tissue biopsy is a rate limiting factor and EGFR mutations are prevalent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract